Brain Cancer Clinical Trials

Showing 1021-1040 of 1,466 trials

18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma

NCT04001257

Role of 18F-FET PET for grading gliomas according to 2016 WHO classification: value of quantitative and qualitative data obtained by 18F-FET PET for differentiating low grade glioma (WHO II) versus high grade gliomas (WHO III and IV)

Positron Emission TomographyGlioma

University Hospital, Brest60 participantsStarted Jun 2019

Brest, France

UNKNOWNPhase 2

Repurposing Chlorpromazine in the Treatment of Glioblastoma

NCT04224441

This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol, i.e. maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide, in newly diagnosed glioblastoma multiforme patients carrying a hypo-methylated O6-methylguanine-DNA-methyltransferase (MGMT) gene

Glioblastoma MultiformeMGMT-Unmethylated Glioblastoma

Marco G Paggi, MD, PhD41 participantsStarted Dec 2019

Rome, Lazio, Italy • Milan, Lombardy, Italy • Padova, Veneto, Italy

COMPLETEDPhase 1/2

Metformin And Chloroquine in IDH1/2-mutated Solid Tumors

NCT02496741

This phase Ib, open-label, single-center, non-randomized clinical trial will evaluate the toxicity and efficacy of metformin and chloroquine in isocitrate dehydrogenase 1/2-mutated (IDH1/2MT) patients with a glioma, intrahepatic cholangiocarcinoma or chondrosarcoma.

GliomaCholangiocarcinomaChondrosarcoma

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)15 participantsStarted Nov 2015

Amsterdam, North Holland, Netherlands • Amsterdam, North Holland, Netherlands • Leiden, South Holland, Netherlands

18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma

Repurposing Chlorpromazine in the Treatment of Glioblastoma

Metformin And Chloroquine in IDH1/2-mutated Solid Tumors

Related Searches

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Natural History of Patients With Brain and Spinal Cord Tumors

Biomarker-based Algorithm for Diagnosis of Glioma

Genetic Analysis of Brain Tumors

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Molecular Heterogeneity in Multilobar Low-grade Gliomas

PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404

Enhancing Optune Therapy With Targeted Craniectomy

Assessment of Suspected Intracranial Malignancy Using 3'-Deoxy-3'18 F-flourothymidine PET

Biomarker Analysis of Central Nervous System Tumors

Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma

Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma

Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols

Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome

An Efficacy Study Of Ortataxel In Recurrent Glioblastoma

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy